Inventor · disambiguated record
Klaus Dugi
Also filed as: DUGI KLAUS · DUGI KLAUS ANDREAS
17 granted patents·22 pending applications·401 citations·filing 2006–2024
95Inventor score
Top patents by PatentIndex Score
39 records- 0198US8673927B2Uses of DPP-IV inhibitorsDUGI KLAUS·Filed 2010·Granted Mar 18, 2014·63 cites·26 claims
- 0298US8232281B2Uses of DPP-IV inhibitorsDUGI KLAUS·Filed 2007·Granted Jul 31, 2012·110 cites·47 claims
- 0397US8846695B2Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitorDUGI KLAUS·Filed 2010·Granted Sep 30, 2014·49 cites·4 claims
- 0496US9173859B2Uses of DPP IV inhibitorsDUGI KLAUS·Filed 2014·Granted Nov 3, 2015·27 cites·22 claims
- 0596US8551957B2Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivateDUGI KLAUS·Filed 2008·Granted Oct 8, 2013·53 cites·48 claims
- 0693US9457029B2Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptinDUGI KLAUS·Filed 2010·Granted Oct 4, 2016·29 cites·15 claims
- 0792US8853156B2Treatment for diabetes in patients inappropriate for metformin therapyDUGI KLAUS·Filed 2009·Granted Oct 7, 2014·28 cites·25 claims
- 0891US10034877B2Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2016·Granted Jul 31, 2018·11 cites·17 claims
- 0991US2025064819A1Uses of dpp iv inhibitorsBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 1090US10092571B2Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptinBOEHRINGER INGELHEIM INT·Filed 2016·Granted Oct 9, 2018·9 cites·9 claims
- 1189US9486526B2Treatment for diabetes in patients inappropriate for metformin therapyDUGI KLAUS·Filed 2014·Granted Nov 8, 2016·11 cites·14 claims
- 1284US7524822B2Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicamentsBOEHRINGER INGELHEIM INT·Filed 2007·Granted Apr 28, 2009·9 cites·10 claims
- 1383US12171767B2Uses of DPP IV inhibitorsBOEHRINGER INGELHEIM INT·Filed 2022·Granted Dec 24, 2024·0 cites·19 claims
- 1480US2025312456A1Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 1576US12312352B2Use of a DPP-4 inhibitor in SIRS and/or sepsisBOEHRINGER INGELHEIM INT·Filed 2022·Granted May 27, 2025·0 cites·8 claims
- 1673US11291668B2Uses of DPP IV inhibitorsBOEHRINGER INGELHEIM INT·Filed 2020·Granted Apr 5, 2022·0 cites·1 claims
- 1772US2022323434A1Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 1870US8202884B2Treatment of type 2 diabetesDUGI KLAUS·Filed 2006·Granted Jun 19, 2012·2 cites·13 claims
- 1970US2021093633A1Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2020·Application pending·0 cites
- 2069US2018353513A1Uses of dpp iv inhibitorsBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 2168US2019000855A1Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptinBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 2266US10080754B2Uses of DPP IV inhibitorsBOEHRINGER INGELHEIM INT·Filed 2016·Granted Sep 25, 2018·0 cites·2 claims
- 2364US2024424006A1Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosisVANDRIA SA·Filed 2024·Application pending·0 cites
- 2462US2019105321A1Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 2562US2024139149A1Therapeutic uses of urolithin derivativesVANDRIA SA·Filed 2023·Application pending·0 cites
- 2661US7838500B2Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicamentsAJINOMOTO KK·Filed 2009·Granted Nov 23, 2010·0 cites·26 claims
- 2761US2020046713A1Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptinBOEHRINGER INGELHEIM INT·Filed 2019·Application pending·0 cites
- 2861US2018271859A1Treatment for diabetes in patients inappropriate for metformin therapyBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 2960US2016000798A1Uses of dpp iv inhibitorsBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 3060US2010298243A1Combination therapy with sglt-2 inhibitors and their pharmaceutical compositionsBOEHRINGER INGELHEIM INT·Filed 2007·Application pending·0 cites
- 3158US2011098240A1Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitorBOEHRINGER INGELHEIM INT·Filed 2008·Application pending·0 cites
- 3256US2019202833A1Use of a dpp-4 inhibitor in sirs and/or sepsisBOEHRINGER INGELHEIM INT·Filed 2019·Application pending·0 cites
- 3354US2013303554A1Use of a dpp-4 inhibitor in sirs and/or sepsisKLEIN THOMAS·Filed 2013·Application pending·0 cites
- 3453US2017189437A1Combination therapy with sglt-2 inhibitors and their pharmaceutical compositionsBOEHRINGER INGELHEIM INT·Filed 2017·Application pending·0 cites
- 3550US2013096076A1Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitorBOEHRINGER INGELHEIM INT·Filed 2012·Application pending·0 cites
- 3649US2016030385A1Combination therapy with sglt-2 inhibitors and their pharmaceutical compositionsBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 3745US2010317575A1Pharmaceutical composition comprising a pyrazole-o-glucoside derivativeBOEHRINGER INGELHEIM INT·Filed 2008·Application pending·0 cites
- 3842US2007072813A1Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivativesHIMMELSBACH FRANK·Filed 2006·Application pending·0 cites
- 3941US2013345262A1Method for prevention of strokeDUGI KLAUS·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Klaus Dugi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →